liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Assaying cardiac biomarkers for toxicity testing using biosensing and cardiomyocytes derived from human embryonic stem cells
Linköping University, Department of Physics, Chemistry and Biology, Biotechnology. Linköping University, Faculty of Science & Engineering.
Cellartis AB, Gothenburg, Sweden .
University of Gothenburg.
Linköping University, Department of Physics, Chemistry and Biology, Biotechnology. Linköping University, The Institute of Technology.
Show others and affiliations
2010 (English)In: JOURNAL OF BIOTECHNOLOGY, ISSN 0168-1656, Vol. 150, no 1, 175-181 p.Article in journal (Refereed) Published
Abstract [en]

Human embryonic stem cell (hESC) derived cardiomyocytes are in the present study being used for testing drug-induced cardiotoxicity in a biosensor set-up. The design of an in vitro testing alternative provides a novel opportunity to surpass previous methods based on rodent cells or cell lines due to its significantly higher toxicological relevance. In this report we demonstrate how hESC-derived cardiomyocytes release detectable levels of two clinically decisive cardiac biomarkers, cardiac troponin T and fatty acid binding protein 3, when the cardiac cells are exposed to the well-known cardioactive drug compound. doxorubicin. The release is monitored by the immuno-biosensor technique surface plasmon resonance, particularly appropriate due to its capacity for parallel and high-throughput analysis in complex media.

Place, publisher, year, edition, pages
Elsevier Science B.V., Amsterdam. , 2010. Vol. 150, no 1, 175-181 p.
Keyword [en]
In vitro toxicity testing, hESC-derived cardiomyocytes, Doxorubicin, Biosensors, Surface plasmon resonance. SPR
National Category
Engineering and Technology
Identifiers
URN: urn:nbn:se:liu:diva-62153DOI: 10.1016/j.jbiotec.2010.06.023ISI: 000283693600025OAI: oai:DiVA.org:liu-62153DiVA: diva2:371280
Available from: 2010-11-19 Created: 2010-11-19 Last updated: 2015-05-29

Open Access in DiVA

No full text

Other links

Publisher's full text

Authority records BETA

Andersson, HenrikKågedal, BertilMandenius, Carl-Fredrik

Search in DiVA

By author/editor
Andersson, HenrikKågedal, BertilMandenius, Carl-Fredrik
By organisation
BiotechnologyFaculty of Science & EngineeringThe Institute of TechnologyClinical ChemistryFaculty of Health SciencesDepartment of Clinical Chemistry
Engineering and Technology

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 168 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf